Catalent to buy $1.2bn gene therapy company

17-04-2019

Catalent to buy $1.2bn gene therapy company

nespix / Shutterstock.com

Contract drug manufacturer Catalent has agreed to acquire Paragon Bioservices, a viral vector development and manufacturing partner for gene therapies, for $1.2 billion.


Catalent, Paragon Bioservices, mergers and acquisitions, M&A, contract manufacturer, gene therapies

LSIPR